PubMed Health⌕ Search

PubMed · 12608799

Conformation of secondary amides. A predictive algorithm that correlates DFT-calculated structures and experimental proton chemical shifts.

Abstract

The magnetic deshielding caused by the amido group on CON-CHalpha protons of secondary amides can easily be correlated with DFT-based structures at the B3LYP/6-31G level of theory via a novel algorithm that refines previous models, such as the classical McConnell equation. The shift is given by delta = a + 2.16 cos2(alpha - 35)/d, where alpha denotes the virtual dihedral angle resulting from linking the carbonyl and the alpha-carbons and d is the distance (A) between the shifted proton and the carbonyl oxygen. Notably, in this equation a is a parameter that can be optimized for different solvents, namely, CDCl3, DMSO-d6, and D2O. For the development of these correlations, the preferential conformation of amides is taken from the optimized structures in the gas phase obtained at the DFT level. The deshielding on anti and gauche protons in both rotamers of (Z)-acetamides and E/Z isomers of formamides has been evaluated. This methodology has proved to be highly reliable, allowing us to discard ab initio or DFT conformational arrangements when shifts calculated by the above-mentioned equation differ from the experimental values. Thus, the anti disposition between the CHalpha proton and the N-H bond appears to be the more stable conformation of simple amides. For amides bearing only one proton at Calpha, a local syn minimum can equally be characterized. The rotational barriers around the CON-alkyl bond along with the pyramidalization of the amido group have also been reassessed. As the conformation is taken away from anti or local syn minima, the nonplanarity of the amido group appears to increase.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Martín Avalos, Reyes Babiano, José L Barneto, Pedro Cintas, Fernando R Clemente, José L Jiménez, Juan C Palacios. 2003-03-07. Conformation of secondary amides. A predictive algorithm that correlates DFT-calculated structures and experimental proton chemical shifts.. https://doi.org/10.1021/jo026695z

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗